Chen Jia, Zhang Wei-Wei, Chen Ke-Hong, Lin Li-Rong, Dai Huan-Zi, Li Kai-Long, Zhang Jian-Guo, Zheng Lu-Quan, Fu Bi-Qiong, He Ya-Ni
Department of Nephrology, Daping Hospital, Third Military Medical University, Chongqing, China.
Department of Nephrology, Daping Hospital, Third Military Medical University, Chongqing, China
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F273-F281. doi: 10.1152/ajprenal.00689.2016. Epub 2017 Mar 29.
Tubulointerstitial injury (TII) plays a crucial role in the progression of diabetic nephropathy (DN), but lack of specific and sensitive biomarkers for monitoring TII in DN management. This study is to investigate whether urinary decoy receptor 2 (uDcR2) could serve as a novel noninvasive biomarker for assessing TII in DN. We recruited 311 type 2 diabetics and 139 DN patients who were diagnosed by renal biopsy. uDcR2 levels were measured by ELISA, and renal DcR2 expression was detected immunohistochemically. Associations between uDcR2 and renal DcR2 and renal functional parameters were evaluated. Receiver operating characteristics (ROC) curve analyzed area under the curve (AUC) of uDcR2 for assessing TII. Double staining was undertaken for renal DcR2 with proximal and distal tubular markers; senescent markers p16, p21, and senescence-associated β-galactosidase (SA-β-gal); and fibrotic markers collagen I and IV. We found DcR2 was primarily expressed in renal proximal tubules; uDcR2 levels were elevated per albuminuria stratum and correlated with renal functional parameters in diabetics and were associated with percentage of tubular DcR2 and TII score in DN. The uDcR2 had an AUC of 0.909 for assessing TII in DN by ROC analysis. Almost all tubular DcR2 was coexpressed with p16 and p21, and nearly more than one-half of tubular DcR2 was positive for SA-β-gal, primarily in collagen I- and IV-positive regions of DN. Our results indicate uDcR2 could potentially serve as a novel biomarker for TII and may reflect senescence of renal proximal tubular cells in DN pathogenesis.
肾小管间质损伤(TII)在糖尿病肾病(DN)进展中起关键作用,但在DN管理中缺乏用于监测TII的特异性和敏感性生物标志物。本研究旨在探讨尿诱饵受体2(uDcR2)是否可作为评估DN中TII的新型非侵入性生物标志物。我们招募了311例2型糖尿病患者和139例经肾活检确诊的DN患者。通过酶联免疫吸附测定法(ELISA)测量uDcR2水平,并通过免疫组织化学检测肾组织中DcR2的表达。评估uDcR2与肾组织DcR2及肾功能参数之间的关联。采用受试者工作特征(ROC)曲线分析uDcR2评估TII的曲线下面积(AUC)。对肾组织DcR2与近端和远端肾小管标志物、衰老标志物p16、p21和衰老相关β-半乳糖苷酶(SA-β-gal)以及纤维化标志物I型和IV型胶原进行双重染色。我们发现DcR2主要表达于肾近端小管;uDcR2水平在各蛋白尿分层中均升高,且与糖尿病患者的肾功能参数相关,在DN中与肾小管DcR2百分比及TII评分相关。通过ROC分析,uDcR2评估DN中TII的AUC为0.909。几乎所有肾小管DcR2均与p16和p21共表达,且近一半以上的肾小管DcR2 SA-β-gal染色呈阳性,主要位于DN的I型和IV型胶原阳性区域。我们的结果表明,uDcR2可能作为TII的新型生物标志物,并可能反映DN发病机制中肾近端小管细胞的衰老。